| Attacking
the
nation's
No.
1
killer:
Statin
and
niacin
treatment
reduces
risk
of
heart
attack
by
70
percent,
can
reverse
arterial
buildup
Website:
University
of
Washington
NEW
ORLEANS
(Nov.
13)
--
Treatment
with
a
combination
of
statin
and
niacin
can
slash
the
risk
of
hospitalization
for
chest
pain
or
a
heart
attack
by
70
percent
among
patients
who
are
likely
to
suffer
heart
attacks
and/or
death
from
cardiovascular
problems,
according
to
a
study
presented
here
by
researchers
at
the
University
of
Washington
School
of
Medicine.
The
treatment
combines
two
already
well-known
ways
of
improving
cardiac
health:
the
use
of
a
statin
drug
to
lower
levels
of
the
"bad"
cholesterol,
LDL,
and
the
use
of
niacin
to
boost
levels
of
the
"good"
cholesterol,
HDL.
The
study
found
that
use
of
this
combined
treatment,
in
people
with
low
levels
of
good
cholesterol
and
average
levels
of
bad
cholesterol,
could
even
remove
plaque
buildup
in
the
arteries.
Cardiovascular
disease
is
the
No.
1
killer
in
the
Western
Hemisphere.
At
the
start
of
the
study
and
again
after
three
years
of
treatment,
doctors
took
angiograms
of
the
patients'
arteries.
The
angiograms
showed
that
in
most
of
the
patients
who
received
the
combination
treatment,
plaque
buildup
had
actually
decreased.
"This
is
the
first
demonstration
of
a
striking
clinical
benefit
from
combination
drug
therapy
for
a
common
type
of
coronary
disease
patient,"
said
Dr.
B.
Greg
Brown,
a
cardiologist
and
UW
professor
of
medicine.
Researchers
are
finishing
up
their
analysis
of
the
study
data,
and
plan
to
submit
their
report
this
winter
for
publication.
Brown
is
the
study's
lead
author.
The
results
were
presented
in
New
Orleans
on
Nov.
13
at
the
Scientific
Sessions
of
the
American
Heart
Association.
"This
interesting
study
is
a
good
demonstration
of
the
enormous
value
of
cholesterol
management
in
patients
with
coronary
disease,"
said
Dr.
Claude
Lenfant,
director
of
the
National
Heart,
Lung,
and
Blood
Institute,
which
funded
the
study.
The
same
study
found
that
a
mixture
of
antioxidant
vitamins
had
no
effect
on
cardiovascular
outcomes.
Scientists
are
not
sure
why
this
is
so,
since
there
has
been
laboratory
evidence
that
suggests
antioxidants
should
be
helpful.
"More
research
and
larger
studies
are
needed
to
confirm
the
lack
of
effectiveness
of
antioxidant
vitamins
on
risk
for
coronary
events,"
Lenfant
said.
Brown
was
involved
in
the
first
studies
in
the
late
1980s
that
showed
that
a
kind
of
statin,
lovastatin,
could
reduce
the
occurrence
of
major
cardiovascular
events
by
about
25
to
35
percent.
Giving
statins
to
people
with
cardiovascular
disease
is
now
common.
"What
you
expect
with
statins
is
a
slowing
of
the
disease
progression,
but
not
a
stopping.
Arteries
continue
to
get
narrower,
but
not
as
fast,"
Brown
said.
"But
when
niacin
is
combined
with
a
statin,
the
artery
blocking
actually
improves,
on
average."
Brown
and
colleagues
surmised
that
combining
simvastatin
with
niacin
might
prevent
even
more
heart
attacks
and
such
cardiac
events.
The
goal
would
be
to
reduce
plaque
buildup.
That's
important
because
the
cholesterol-rich
plaque
is
what
can
clog
artery
walls
and
lead
to
fatal
complications.
The
statin
lowers
blood
levels
of
LDL,
which
is
called
the
"bad"
cholesterol
because
it
is
more
likely
to
clog
ateries.
Niacin,
or
Vitamin
B3,
is
the
best
agent
known
to
raise
blood
levels
of
HDL,
which
helps
dissolve
cholesterol
deposits
from
the
artery
walls.
The
160
patients
involved
in
the
study
had
low
levels
of
good
HDL
cholesterol
(a
level
of
35
or
less).
At
least
four
out
of
every
10
people
with
coronary
artery
disease
fit
this
profile.
But
the
study
results
may
have
implications
for
other
people
with
coronary
diseases.
They
would
have
even
higher
levels
of
HDL
-
and
having
higher
levels
of
the
good
cholesterol
should
only
help
them,
Brown
said.
Some
patients
in
this
study
received
simvastatin
and
niacin,
while
others
received
antioxidants.
A
third
group
received
three
treatments
while
a
fourth,
control,
group
received
placebos.
All
patients
received
exercise
training
and
dietary
counseling.
The
results
for
those
receiving
statin
and
niacin
were
startlingly
different
than
the
others.
The
average
level
of
HDL
increased
from
31
to
38,
while
the
average
LDL
dropped
from
125
to
76
--
that
is
considered
an
extremely
good
level
of
the
bad
cholesterol.
Angiograms
showed
that
most
of
these
people
had
no
additional
plaque
buildup
over
the
years.
In
many
of
them,
the
amount
of
plaque
actually
decreased.
"What
we
saw
was
a
reversal
of
the
disease,"
Brown
said.
"The
patients'
arteries,
on
average,
had
stopped
narrowing
and
begun
to
improve."
The
study
involved
use
of
niacin
at
moderately
high
and
carefully
supervised
levels.
Brown
said
that
people
should
only
take
niacin
under
a
doctor's
supervision,
because
in
some
patients,
the
doctor
may
wish
to
monitor
the
patient's
liver.
Rarely,
the
unsupervised
use
of
niacin
can
cause
severe
liver
problems,
including
liver
failure.
The
study
had
included
antioxidants
because
there
has
been
considerable
evidence
that
they
should
help
protect
against
the
basic
mechanisms
for
cholesterol
buildup.
The
antioxidants
involved
in
this
study
include
Vitamins
C,
E,
beta
carotene
and
selenium.
Back
to HEALTH
|